More interestingly, 1,25(OH)2D3 treatment together with interfering the expression of hCAP18/LL-37 significantly enhanced the antitumor activity of 1,25(OH)2D3 in the HCC xenograft tumor. This evidence concerns the gene CAMP and hepatocellular carcinoma.